Factors predicting intolerance to definitive conventional radiotherapy in geriatric patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rim, Chai Hong | - |
dc.contributor.author | Yoon, Won Sup | - |
dc.contributor.author | Lee, Jung Ae | - |
dc.contributor.author | Yang, Dae Sik | - |
dc.contributor.author | Lee, Nam Kwon | - |
dc.contributor.author | Park, Young Je | - |
dc.contributor.author | Kim, Chul Yong | - |
dc.date.accessioned | 2021-09-02T06:11:01Z | - |
dc.date.available | 2021-09-02T06:11:01Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2018-10 | - |
dc.identifier.issn | 0179-7158 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/73031 | - |
dc.description.abstract | Although radiotherapy can be administered with a relatively low therapeutic burden, many elderly patients do not complete radiotherapy. In order to predict intolerance during radiotherapy, this study retrospectively analyzed the frequency of and risk factors for radiotherapy interruption among geriatric patients. From September 2009 to December 2016, 353 patients aged ae70 years received definitive radiotherapy with a conventionally fractionated schedule. "Total interruption" included completion of ae>90% of a planned radiotherapy, temporary discontinuation, and treatment-related mortality within 2 months. "Early-phase incompletion" and "mid-phase incompletion" represented completion of ae>50 and ae>80% of a planned radiotherapy, respectively. The median age of patients was 74 years. Early- and mid-phase incompletions and total interruption occurred in 4.2, 9.3, and 19.3% of patients, respectively. Total interruption occurred frequently in cancers involving the thorax (27.4%), head and neck (23.1%), abdomen (20.0%), pelvis (17.4%), and breast/extremity (8.1%). The Eastern Cooperative Oncology Group (ECOG) performance score (PaEuro= 0.004 and 0.002), serum albumin level ( 0.016 and 0.002), and the expected 5aEuroyear survival (PaEuro= 0.033 and 0.034) were significant factors for mid-phase incompletion and total interruption. AgeaEuroae 75 years (PaEuro= 0.008), concurrent chemotherapy (PaEuro= 0.017), and the extent of radiation field (PaEuro= 0.027) were factors associated with total interruption. Overall, 19.3% of the elderly patients showed treatment intolerance during conventional radiotherapy. Serum albumin level and ECOG performance score should be considered as surrogate markers for radiotherapy interruption prior to the decision regarding definite conventional radiotherapy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER HEIDELBERG | - |
dc.subject | CELL LUNG-CANCER | - |
dc.subject | ADVANCED RECTAL-CANCER | - |
dc.subject | ELDERLY-PATIENTS | - |
dc.subject | OLDER PATIENTS | - |
dc.subject | CONCURRENT CHEMORADIOTHERAPY | - |
dc.subject | CHEMOTHERAPY TOXICITY | - |
dc.subject | UNITED-STATES | - |
dc.subject | SURVIVAL | - |
dc.subject | COMORBIDITY | - |
dc.subject | MORTALITY | - |
dc.title | Factors predicting intolerance to definitive conventional radiotherapy in geriatric patients | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoon, Won Sup | - |
dc.contributor.affiliatedAuthor | Yang, Dae Sik | - |
dc.contributor.affiliatedAuthor | Lee, Nam Kwon | - |
dc.contributor.affiliatedAuthor | Kim, Chul Yong | - |
dc.identifier.doi | 10.1007/s00066-018-1318-y | - |
dc.identifier.scopusid | 2-s2.0-85047324966 | - |
dc.identifier.wosid | 000446123800004 | - |
dc.identifier.bibliographicCitation | STRAHLENTHERAPIE UND ONKOLOGIE, v.194, no.10, pp.894 - 903 | - |
dc.relation.isPartOf | STRAHLENTHERAPIE UND ONKOLOGIE | - |
dc.citation.title | STRAHLENTHERAPIE UND ONKOLOGIE | - |
dc.citation.volume | 194 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 894 | - |
dc.citation.endPage | 903 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | ADVANCED RECTAL-CANCER | - |
dc.subject.keywordPlus | ELDERLY-PATIENTS | - |
dc.subject.keywordPlus | OLDER PATIENTS | - |
dc.subject.keywordPlus | CONCURRENT CHEMORADIOTHERAPY | - |
dc.subject.keywordPlus | CHEMOTHERAPY TOXICITY | - |
dc.subject.keywordPlus | UNITED-STATES | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | COMORBIDITY | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordAuthor | Risk factors | - |
dc.subject.keywordAuthor | Cancer | - |
dc.subject.keywordAuthor | Elderly | - |
dc.subject.keywordAuthor | Toxicity | - |
dc.subject.keywordAuthor | Life expectancy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.